248 related articles for article (PubMed ID: 25915157)
1. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Alonso S; Su M; Jones JW; Ganguly S; Kane MA; Jones RJ; Ghiaur G
Oncotarget; 2015 Jun; 6(17):14905-12. PubMed ID: 25915157
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
Ghiaur G; Valkenburg KC; Esteb C; Ambinder A; Imus PH; Pienta KJ; Jones RJ
Cancer; 2023 Jun; 129(11):1744-1751. PubMed ID: 36840972
[TBL] [Abstract][Full Text] [Related]
3. Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Su M; Chang YT; Hernandez D; Jones RJ; Ghiaur G
J Cell Mol Med; 2019 Jun; 23(6):4111-4117. PubMed ID: 30920135
[TBL] [Abstract][Full Text] [Related]
4. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid, CYP26, and drug resistance in the stem cell niche.
Alonso S; Jones RJ; Ghiaur G
Exp Hematol; 2017 Oct; 54():17-25. PubMed ID: 28754309
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
9. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
10. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
12. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells.
Rubio R; Abarrategi A; Garcia-Castro J; Martinez-Cruzado L; Suarez C; Tornin J; Santos L; Astudillo A; Colmenero I; Mulero F; Rosu-Myles M; Menendez P; Rodriguez R
Stem Cells; 2014 May; 32(5):1136-48. PubMed ID: 24446210
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
[TBL] [Abstract][Full Text] [Related]
14. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
17. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling.
Ghiaur G; Yegnasubramanian S; Perkins B; Gucwa JL; Gerber JM; Jones RJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16121-6. PubMed ID: 24043786
[TBL] [Abstract][Full Text] [Related]
18. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis.
Modugno F; Knoll C; Kanbour-Shakir A; Romkes M
Breast Cancer Res Treat; 2003 Dec; 82(3):191-7. PubMed ID: 14703066
[TBL] [Abstract][Full Text] [Related]
19. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.
Dani M; Boisvert C; Michaud J; Naud J; Lefrançois S; Leblond FA; Pichette V
Drug Metab Dispos; 2010 Mar; 38(3):357-60. PubMed ID: 20007296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
